Overview
NICE is unable to make a recommendation on vedolizumab (Entyvio) for treating chronic refractory pouchitis after surgery for ulcerative colitis in adults. This is because Takeda did not provide an evidence submission.
Last reviewed: 21 September 2022
Next review: We will review this decision if the company decides to make a submission.